Judge dismisses Seroquel product liability suits
Executive Summary
A judge threw out two lawsuits claiming AstraZeneca failed to provide adequate warning that its atypical antipsychotic Seroquel (quetiapine) increased the risk of diabetes. The suits, brought by Anne Guinn and David Haller, are among more than 7,000 pending in multidistrict litigation in the U.S. District Court of the Middle District of Florida. They were selected as test cases for trial and, on Jan. 30, U.S. District Judge Anne Conway granted AstraZeneca's motion for summary judgment in both. In the Guinn case she ruled that there is "no evidence in the record from which a reasonable juror could conclude that Seroquel contributed substantially to producing Guinn's injury.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.